BRAF and melanoma: For example, PERK mutations in human melanomas have inhibitory functions on PERK activity, and reducing PERK expression by 50% in a BRAF-dependent mouse melanoma model promoted the development of BrafV600E-induced tumors, although complete loss of PERK was tumor suppressive [40].